|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayTECFIDERA SUCCEEDS IN PROTECTING BIOGEN'S MS MARKET SHARE FROM NOVARTIS' GILENYA![]() The MS treatment market has previously been dominated by Biogen's Avonex and Tysabri, and Teva Pharmaceutical's Copaxone -- blockbuster drugs delivered by injection. Combined, those drugs generated sales of $8 billion in 2012. But, a new generation of drugs and upcoming patent expiration for Copaxone are disrupting current treatment protocols and shifting demand to new oral drugs including Novartis' Gilenya and Sanofi's Aubagio. Read more » Labels: Aubagio, Avonex, Biogen, Gilenya, TECFIDERA, Tysabri |